Alveus Therapeutics Raises $160M

In a significant win for Black-led innovation in biotech/health-tech, Alveus Therapeutics (highlighted in recent "Black Innovation" roundups) has exited stealth mode with a massive $160 million in funding.The company is developing alternatives to popular weight-loss drugs like Ozempic, positioning itself as a major player in the life sciences sector for 2026.

• The Scoop: In a massive win for biotech, Alveus Therapeutics launched with $160 million in Series A funding on January 8. They are developing next-gen oral drugs for obesity and metabolic disease that could rival Ozempic.

• Impact on Black Culture & Community: This is a dual-impact story. Economically, it showcases Black leadership in the high-stakes world of biotech venture capital. Culturally, it addresses a health equity crisis; metabolic diseases disproportionately affect Black communities due to systemic food apartheid. A Black-led company solving this issue implies a solution that might prioritize accessibility and trust in medical systems where it has historically been lacking.